Can Anything Stop Drug Companies From Fleeing The U.S. Tax System?

Friday morning, after five spurned bids, , the North Chicago-based pharmaceutical giant finally closed in on a deal to buy Irish drugmaker for $54 billion. One key consequence of the deal: AbbVie will change its tax domicile from Illinois to the U.K., reducing its tax rate.